Next Article in Journal
The Role of Surgical Resection in Unicentric Castleman’s Disease: A Systematic Review
Previous Article in Journal
IPF and CPFE—The Two Different Entities or Two Different Presentations of the Same Disease?
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Inflammatory Myofibroblastic Tumor of the Lung

by
Akshay Khatri
1,
Abhinav Agrawal
2,*,
Rutuja R. Sikachi
2,
Dhruv Mehta
3,
Sonu Sahni
4 and
Nikhil Meena
5
1
Department of Medicine, Westchester Medical Center, Valhalla, NY, USA
2
Division of Pulmonary, Critical Care & Sleep Medicine, Northwell Health — Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY 11040, USA
3
Division of Gastroenterology, Westchester Medical Center, Valhalla, NY, USA
4
Touro College of Osteopathic Medicine, Department of Primary Care, Harlem, NY, USA
5
Division of Pulmonary, Critical Care & Sleep Medicine, University of Arkansas, Little Rock, AR, USA
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2018, 86(1), 27-35; https://doi.org/10.5603/ARM.2018.0007
Submission received: 8 November 2017 / Revised: 5 January 2018 / Accepted: 5 January 2018 / Published: 21 January 2018

Abstract

Inflammatory myofibroblastic tumors (IMT) of the lung, first reported in 1939, are considered a subset of inflammatory pseudo -tumors. They are a distinctive lesions composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of plasma cells, lymphocytes, and eosinophils. IMTs may be benign, invade surrounding structures, undergo malignant transformation, recur or may even metastasize. They can occur due to a genetic mutation or can occur secondary to infectious or autoimmune diseases. Patients may be asymptomatic, or present with cough, hemoptysis, dyspnea, pleuritic pain, constitutional symptoms or pneumonia. In this article we review the pathophysiology, genetics, clinical presentation, imaging findings of IMT of the lung. We also discuss the various surgical and non-surgical treatment options and the prognosis associated with this disease.
Keywords: inflammatory myofibroblastic tumor of the lung (IMT); inflammatory pseudo-tumor (IPT); pulmonary neoplasm; ALK; bronchoscopy inflammatory myofibroblastic tumor of the lung (IMT); inflammatory pseudo-tumor (IPT); pulmonary neoplasm; ALK; bronchoscopy

Share and Cite

MDPI and ACS Style

Khatri, A.; Agrawal, A.; Sikachi, R.R.; Mehta, D.; Sahni, S.; Meena, N. Inflammatory Myofibroblastic Tumor of the Lung. Adv. Respir. Med. 2018, 86, 27-35. https://doi.org/10.5603/ARM.2018.0007

AMA Style

Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. Inflammatory Myofibroblastic Tumor of the Lung. Advances in Respiratory Medicine. 2018; 86(1):27-35. https://doi.org/10.5603/ARM.2018.0007

Chicago/Turabian Style

Khatri, Akshay, Abhinav Agrawal, Rutuja R. Sikachi, Dhruv Mehta, Sonu Sahni, and Nikhil Meena. 2018. "Inflammatory Myofibroblastic Tumor of the Lung" Advances in Respiratory Medicine 86, no. 1: 27-35. https://doi.org/10.5603/ARM.2018.0007

Article Metrics

Back to TopTop